R H Wiltrout
Overview
Explore the profile of R H Wiltrout including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yazawa H, Murakami T, Li H, Back T, Kurosaka K, Suzuki Y, et al.
Cancer Gene Ther
. 2006 Jun;
13(11):993-1001.
PMID: 16763608
Antiangiogenic gene therapy is a promising strategy for cancer treatment, which generally requires highly efficient delivery systems. To date, success of this strategy has depended almost exclusively on the delivery...
2.
Lee J, Seki N, Sayers T, Subleski J, Gruys E, Murphy W, et al.
Cell Immunol
. 2005 Oct;
235(2):145-52.
PMID: 16213477
CD40, a member of the TNF receptor superfamily, is expressed on B cells, dendritic cells, and some tumor cells, including melanoma and bladder carcinoma. In this study, we report that...
3.
Lee J, Sayers T, Back T, Wigginton J, Wiltrout R
Apoptosis
. 2003 May;
8(2):151-60.
PMID: 12766475
Lewis lung carcinoma (3LL) cells were constitutively resistant to Fas-mediated apoptosis, but overexpression of Fas on 3LL cells allowed Fas-mediated apoptosis after crosslinking with agonist anti-Fas antibody (Jo2) in vitro....
4.
Lee J, Back T, Komschlies K, Ruscetti F, Young H, Wiltrout R
In Vivo
. 2001 Nov;
15(4):255-63.
PMID: 11695215
A significant splenomegaly and lymphadenopathy develops during the progressive growth of Lewis Lung (3LL) tumors in mice. Enlarged spleen and lymph nodes occur because of a pronounced increase in granulocytes...
5.
Gruys M, Back T, Subleski J, Wiltrout T, Lee J, Schmidt L, et al.
Cancer Res
. 2001 Aug;
61(16):6255-63.
PMID: 11507080
Interleukin-2-based regimens of biological therapy have shown some clinical promise for the treatment of kidney cancer in humans, although the mechanisms responsible for tumor regression occurring in these patients remain...
6.
Wigginton J, Gruys E, Geiselhart L, Subleski J, Komschlies K, Park J, et al.
J Clin Invest
. 2001 Jul;
108(1):51-62.
PMID: 11435457
Systemic administration of IL-12 and intermittent doses of IL-2 induce complete regression of metastatic murine renal carcinoma. Here, we show that overt tumor regression induced by IL-12/pulse IL-2 is preceded...
7.
Hixon J, Blazar B, Anver M, Wiltrout R, Murphy W
Biol Blood Marrow Transplant
. 2001 Apr;
7(3):136-43.
PMID: 11302547
CD40 stimulation, by either antibody or ligand, has been shown to inhibit the growth of a variety of neoplastic cells, both in vivo and in vitro. In this study, we...
8.
Welniak L, Blazar B, Wiltrout R, Anver M, Murphy W
Transplant Proc
. 2001 Mar;
33(1-2):1752-3.
PMID: 11267498
No abstract available.
9.
Smyth M, Cretney E, Takeda K, Wiltrout R, Sedger L, Kayagaki N, et al.
J Exp Med
. 2001 Mar;
193(6):661-70.
PMID: 11257133
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed by in vitro activated natural killer (NK) cells, but the relevance of this observation to the biological function of NK cells has...
10.
Park J, Gruys M, McCormick K, Lee J, Subleski J, Wigginton J, et al.
J Immunol
. 2001 Mar;
166(6):3763-70.
PMID: 11238618
The IFN-gamma-inducible proteins monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2) can contribute to IL-12-induced antiangiogenic and leukocyte-recruiting activities, but the extent to which leukocytes vs parenchymal...